SLU-PP-332 Purity: 339 Lab Tests Across 166 Identified Manufacturers
5 studies on SLU-PP-332 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently tracks 339 published third-party lab tests of SLU-PP-332 across 166 identified manufacturers. Among reports with a positive numeric purity result, the average is 98.93%. Within this published corpus, 4 positive purity results were below 90%, and 29 reports showed measured quantity more than 10% below the label claim. These are batch-level observations, not guarantees of product identity, safety, or vendor quality.
SLU-PP-332 average prices
As of 2026-09-03, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $14.50 | $14.50–$14.50 | $2.90 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
We tested 339 SLU-PP-332 batches across 166 identified manufacturers
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
Within that total, 64 batches have unresolved manufacturer identity. They remain in corpus-level lab evidence and are excluded from named-manufacturer rankings.
Top 3 vendor evidence profiles for SLU-PP-332
Eligible vendors have at least 2 deduplicated tests and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and test count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes tested batches, not every product or shipment, and is not an endorsement.
| Rank | Manufacturer | Tests | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 7 | 99.55% | 0 of 7 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #2 | 7 | 99.23% | 0 of 6 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → | |
| #3 | 10 | 99.85% | 0 of 5 (0.0%) 0 0% / not detected · 0 wrong compound · 5 unclassified | Reveal with Pro → |
Manufacturer identities are included with Pro. Batch counts and lab measurements remain visible.
Recent certificates: #101017 (99.7%) · #99610 (99.57%) · #99820 (99.43%) · #100738 (99.34%) · #94636 (99.71%) · #80927 (99.65%)
SLU-PP-332 studies and clinical research
-
Targeting ERRs Shows Promise Against Age-Related Muscle Wasting and Inactivity
This pilot study provides compelling evidence that Estrogen-Related Receptors (ERRs) represent a highly promising and previously under-explored therapeutic target for combating sarcopenia and disuse-induced muscle atr…
-
Synthetic ERR Agonist Shows Broad Efficacy Against Metabolic Syndrome
This study provides compelling evidence that a synthetic ERR agonist can effectively mitigate multiple symptoms of metabolic syndrome in a preclinical model, underscoring the significant therapeutic potential of targe…
-
Novel Agonists Boost Heart Metabolism to Treat Heart Failure
This research highlights the therapeutic potential of targeting ERR pathways to combat heart failure by directly addressing its underlying metabolic dysfunction. By enhancing the heart's ability to generate energy and…
-
Identifying SLU-PP-332 Metabolites for Enhanced Anti-Doping Control
-
Novel Compound SLU-PP-332 Shows Promise Against Colorectal Cancer
Research tools
Free, no account — handy when you're working with SLU-PP-332.
